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SHORT REPORT Open Access
A Disease Register for ME/CFS: Report of a Pilot
Study
Derek Pheby1*, Eliana Lacerda2, Luis Nacul2, Maria de Lourdes Drachler3, Peter Campion4, Amanda Howe3,
Fiona Poland3, Monica Curran3, Valerie Featherstone4, Shagufta Fayyaz2, Dikaios Sakellariou5 and
José Carlos de Carvalho Leite3
Abstract
Background: The ME/CFS Disease Register is one of six subprojects within the National ME/CFS Observatory, a
research programme funded by the Big Lottery Fund and sponsored by Action for ME. A pilot study in East Anglia,
East Yorkshire, and London aimed to address the problem of identifying representative groups of subjects for
research, in order to be able to draw conclusions applicable to the whole ME/CFS population.
While not aiming for comprehensive population coverage, this pilot register sought to recruit participants with ME/
CFS in an unbiased way from a large population base. Those recruited are constituting a cohort for long-term
follow-up to shed light on prognosis, and a sampling frame for other studies.
Findings: Patients with unidentified chronic fatigue were identified in GP databases using a READ-code based
algorithm, and conformity to certain case definitions for ME/CFS determined. 29 practices, covering a population
aged 18 to 64 of 143,153, participated.
510 patients with unexplained chronic fatigue were identified. 265 of these conformed to one or more case
definitions. 216 were invited to join the register; 160 agreed. 96.9% of participants conformed to the CDC 1994
(Fukuda) definition; the Canadian definition defined more precisely a subset of these. The addition of an
epidemiological case definition increased case ascertainment by approximately 4%. A small-scale study in a
specialist referral service in East Anglia was also undertaken.
There was little difference in pattern of conformity to case definitions, age or sex among disease register
participants compared with subjects in a parallel epidemiological study who declined to participate.
One-year follow-up of 50 subjects showed little change in pain or fatigue scores. There were some changes in
conformity to case definitions.
Conclusions: Objective evaluation indicated that the aim of recruiting participants with ME/CFS to a Disease
Register had been fulfilled, and confirmed the feasibility of our approach to case identification, data processing,
transmission, storage, and analysis. Future developments should include expansion of the ME/CFS Register and its
linkage to a tissue sample bank and post mortem tissue archive, to facilitate support for further research studies.
Background
The myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS) Disease Register pilot feasibility study, in East
Anglia, East Yorkshire, and London, is part of the
National ME/CFS Observatory project, funded by the
Big Lottery Fund and sponsored by the charity Action
for ME. The programme is managed in close liaison
with people with ME/CFS and carers.
The study objectives were to:-
• establish a disease register for ME/CFS.
• demonstrate that it can be managed in accordance
with legal and ethical requirements.
• assess the effectiveness and comprehensiveness of
case ascertainment methods in different communities.
• determine whether or not duplicate entries could be
readily detected.
• assess the feasibility of regular follow-up.
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• confirm that the data transmission and processing
methods were demonstrably secure.
• involve people with ME/CFS and carers in the man-
agement of the project.
Disease registers, including the American Veterans’
Affairs Gulf War Registry [1,2] and twin registries, have
been used to study ME/CFS. Swedish Twin Registry stu-
dies showed CFS to be associated with premorbid stress
[3-5]. American twin registry studies [6,7] showed that
the prevalence of fatiguing illness depended on case
definition [8]. A disease-specific twin registry for chronic
fatigue has now been established [9].
A 2002 review of disease registers in England [10]
asserted that in chronic diseases “... an accurate well-
maintained register is a prerequisite to providing com-
prehensive and coordinated care” [11]. With govern-
mental commitment to establish disease registers in
mind [12], the authors identified approximately 250 dis-
ease registers recording all cases of a disease in a popu-
lation, which they distinguished from clinical databases
[10]. Our study did not aim at comprehensive popula-
tion coverage, which would have been unrealistic as
many doctors do not recognise the existence of ME/
CFS, nor diagnose it [13]. Rather, the study addresses a
problem of ME/CFS research, where frequently findings
of intervention studies in unrepresentative groups, e.g.
excluding severely incapacitated patients, are extrapo-
lated to the whole ME/CFS population. The NICE
guidelines on ME/CFS [14] have been criticised on these
grounds [15]. Similar problems arise in epidemiological
studies [16].
The disease register sought to recruit participants in
an unbiased way from a large population. They will be
followed up long-term, since little is known about prog-
nosis [17] The register will also constitute a sampling
frame for other studies, including intervention studies,
to generate results capable of being generalised to the
whole ME/CFS population.
Methods
A descriptive epidemiological study of ME/CFS was car-
ried out in three English regions. General practices in
East Yorkshire and East Anglia were invited to partici-
pate by the local academic Primary Care Departments
in the universities of Hull and East Anglia respectively,
and in London by the relevant Primary Care Trust.
Patients with unexplained chronic fatigue were identified
in GPs’ computerised databases by an algorithm identi-
fying READ diagnostic terms indicating probable or pos-
sible ME/CFS, while excluding other fatiguing
conditions. The primary diagnostic terms (indicating
probable ME/CFS) were chronic fatigue syndrome, post
viral asthenic syndrome, neurasthenia, fatigue syndrome,
post infectious encephalitis, and fibromyalgia. Secondary
diagnoses, indicating possible ME/CFS, were ‘Tired all
the time’ (TATT), asthenia, tiredness, fatigue, and neur-
asthenia or nervous debility. The exclusions were Addi-
son’s disease, Cushing’s syndrome, hypothyroidism,
hyperthyroidism, diabetes mellitus, anaemia, iron defi-
ciency or overload, cancer, rheumatological and auto-
immune disorders (rheumatoid arthritis, lupus, poly-
myositis and polymyalgia rheumatic), AIDS, multiple
sclerosis, parkinsonism, myasthenia gravis, B12 defi-
ciency, active infections (tuberculosis, chronic hepatitis),
alcohol or substance abuse, sleep apnoea, major psychia-
tric disorders including bipolar disorder, psychosis and
anorexia/bulimia, and major organ failure.
GPs reviewed patients with primary diagnoses to
exclude those with symptoms explicable by other diag-
noses, or whose participation was contraindicated for per-
sonal or clinical reasons. Those with secondary diagnoses
were also reviewed. Patients identified were invited to par-
ticipate in the descriptive epidemiological study, and sent
an information sheet and consent form, and symptom
assessment instruments. Data was entered locally and
transmitted using secure on-line communications to the
London School of Hygiene and Tropical Medicine
(LSHTM), where a web-based bespoke system was hosted
on a UNIX web server using PHP and MySQL database.
The system used an encrypted Secure Sockets Layer (SSL)
to encrypt data interactions. Personal data was also
encrypted. A computerised algorithm was applied to the
symptom assessment data to identify subjects who fulfilled
at least one of three case definitions, i.e.
(a) The CDC 1994 (Fukuda) definition [18], the most
widely used case definition in ME/CFS research,
(b) The Canadian definition [19], recently promulgated
and thought to define more precisely patients with
unequivocal ME/CFS,
(c) An epidemiological case definition [20], intended
to be a robust yet simplified and more inclusive defini-
tion of ME/CFS for epidemiological studies. This has
two levels, 1, identifying mild to moderate disease, and
2, identifying more severely affected subjects, with a dif-
ferent symptom profile.
Subjects conforming to at least one case definition,
unless they did not know or did not accept that they
had ME/CFS, were contacted and invited to participate
in the Disease Register. A subset of participant data,
comprising and GP practice identifiers, contact details,
personal characteristics (date of birth, gender, ethnicity),
details of consent, and conformity to case definitions,
was then held in the LSHTM system.
Participants completed other assessment instruments,
including SF-36 [21] and visual analogue scales for pain
and fatigue. After one year, a sample of fifty participants
was followed up with a further questionnaire, to assess
effectiveness of follow-up procedures.
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A small-scale study of cases attending a specialist
referral service in East Anglia (i.e. covering the area of
some participating practices) was also undertaken, to
increase the basis of recruitment, and to examine the
effectiveness of duplicate entry identification..
For analysis, a severe case is one with (i) tiredness/fati-
gue most days, (ii) unable to do activities because of
tiredness/fatigue, (iii) activities reduced more than 50%
since falling ill, (iv) fatigue debilitating and affecting
mental and physical functioning, and (v) pain score
eight out of ten, and/or fatigue score eighty out of a
hundred, or more.
The study was approved by the London Multi-Centre
Research Ethics Committee, and the Ethics Committee
of LSHTM.
Results
The study reviewed case ascertainment methods, proce-
dures for handling duplicate registrations, validity and
appropriateness of primary care-based data collection
methods in ethnically and socially diverse populations, fol-
low-up arrangements, and effectiveness and legal and ethi-
cal compliance of data management, including data access,
data security, and monitoring data quality, i.e. complete-
ness, comprehensiveness, accuracy and timeliness. We
established arrangements for accountability, reporting and
publicity and a clinical network to support the work of the
register. These are considered in the ‘Discussion’ section.
The 29 participating practices covered a population
aged 18 to 64 inclusive of 143,153. Five practices were
in East Anglia and five in London. There were nineteen,
on average smaller, practices in East Yorkshire. Among
this population, 510 patients with unexplained chronic
fatigue were identified, and 265 conformed to one or
more case definitions. 216 were invited to participate in
the register, and 160 agreed.
Conformity to Case Definitions
Figure 1 illustrates distribution by case definition. Most
cases (96.9%) fulfilled the CDC 1994 (Fukuda) definition,
while the Canadian definition defined more precisely a
subset of these. Use of the epidemiological case defini-
tion increased overall ascertainment by nearly 4%.
There was little difference in conformity to case
definitions between disease register participants, non-
participants or epidemiological study subjects overall
(Table 1).
Of five cases conforming to the epidemiological case
definition but not to the CDC (1994) definition, three
manifested only three of the 1994 CDC definition’s
minor criteria, not the required four, one had other ill-
nesses which were exclusions from the CDC 1994 defi-
nition, while the fifth had illness of indefinite onset.
Cases meeting the Canadian definition were compared
with CDC (1994) positive cases that did not (Table 2).
There were no significant differences in age or sex dis-
tribution. None of the participants who reported fatigue
less frequently than every day, or who did not regard
their fatigue as debilitating, conformed to the Canadian
definition. Those conforming to the Canadian definition
tended to report a greater impact of fatigue on activities,
a greater reduction in activity levels since falling ill,
higher pain levels, and higher fatigue levels on
recruitment.
Table 3 compares age group and sex distribution, and
table 4 levels of severity, in Register participants and
non-participants.
80.0% of males approached agreed to participate, and
72.4% of females. Subjects from East Anglia were most
Figure 1 The inter-relationship of diagnostic definitions used
in the ME/CFS Disease Register Pilot Study.
Table 1 Conformity of Epidemiological Study and Disease Register Participants to Case Definitions
Case
Definition
Epidemiological Study Disease Register
All subjects Subjects not in disease register
No.
cases
% total
(95% confidence interval)
No.
cases
% total
(95% confidence interval)
No.
cases
% total
(95% confidence interval)
Fukuda 282 96.9 (94.8 - 99.0) 127 96.9 (93.9 - 100.0) 155 96.9 (94.1 - 99.7
Canadian 154 52.9 (44.9 - 61.0) 57 43.5 (30.4 - 56.6) 97 60.6 (50.7 - 70.5)
TOTAL 291 100.0 131 100.0 160 100.0
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Table 2 Fukuda definition-positive subjects conforming or not conforming to the Canadian case definition
Cases
fulfilling
case
definition
(n = 122)
Cases not
fulfilling
case
definition
(n = 87)
95% confidence interval
(difference in percentages)
No. %
total
No. %
total
Age Group: < 25 1 0.8 4 4.6 -8.6 - 1.0
25-34 15 12.3 6 6.9 -2.7 - 1.5
35-44 32 26.2 19 21.8 -7.5 - 1.3
45-54 43 35.2 28 32.2 -10.2 - 1.3
55-64 27 22.1 30 34.5 -25.0 - 0.3
65+ 4 3.3 1 1.1 -1.8 - 6.1
Sex: Male 25 20.5 15 17.2 -7.7 - 14.2
Female 97 79.5 72 82.8 -14.2 - 7.7
How often do you have tiredness/fatigue?
Occasionally 0 0.0 1 1.1 -3.4 - 1.1
< 3 times/week 0 0.0 7 8.0 -13.9 - -2.2
Every day or nearly every day 122 100.0 79 90.8 3.0 - 15.4
Were your activities (personal, social, professional, at home) affected by the
symptoms of tiredness/fatigue?
Not at all 0 0.0 0 0.0 0.0- 0.0
A little 0 0.0 0 0.0 0.0- 0.0
Needed to reduce 11 9.0 36 41.4 -44.1 - -20.6
Can no longer do 111 91.0 51 58.6 20.6 - 44.1
Would you say that your activities were reduced to < 50% than before you fell
ill?
Yes, by > 50% 116 95.1 70 80.5 5.3 - 24.0
No, by 50% or less 4 3.3 10 11.5 -15.8 - -0.7
Don’t know 2 1.6 6 6.9 -11.2 - 0.6
Would you say that your fatigue is debilitating and affects your mental and
physical functioning?
Yes 122 100.0 79 90.8 3.0 - 15.4
No 0 0.0 4 4.6 -9.1 - -0.1
Don’t know 0 0.0 3 3.4 -7.4 - 0.5
Pain level (where 0 = no pain, and 10 = pain as bad as possible)
Mean 6.0 4.6
95% confidence interval 5.6 - 6.4 2.5 - 3.1
Standard deviation 2.4 2.8
Median 6 5
Interquartile range 5-8 2-7
No. reporting no pain 2 9
No. reporting maximum pain 5 3
Fatigue level on recruitment (where 0 = no problem, and 100 = the most
severe health impediment)
Mean 65.7 54.3
95% confidence interval 61.0 - 70.4 50.0 - 58.6
Standard deviation 26.1 21.0
Median 70 50
Interquartile range 50-80 50-70
No. reporting no fatigue 2 2
No. reporting max. possible fatigue 15 1
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likely to agree, and those from London least likely.
Those not participating tended to report more severe
symptoms than register participants, but this was not
statistically significant.
Duration of illness prior to recruitment varied from
18 months to 27 years, with a mean of 127.3 months
(standard deviation = 84.1 months), and a median of
108 months. There was no difference between males
(mean duration prior to recruitment = 128.1 months)
and females (mean duration prior to recruitment =
127.1 months) in this respect. The results regarding
duration of illness prior to recruitment are summarised
in table 5.
Follow-Up Results
Pain and fatigue levels were recorded in fifty disease
register subjects followed up after one year. Pain was
assessed on a scale of 0 to 10, where 0 indicated no
pain and 10 maximum pain. Fatigue scores ranged from
0 to 100, where 0 indicated no fatigue with exercise and
100 indicated maximum fatigue, bedridden, and unable
to self-care. There was little change in either. The mean
pain score on recruitment was 4.9, (median 5.0, inter-
quartile range 2.0-7.0; n = 50), and after one year the
mean was 5.0 (median 5.7, interquartile range 2.6-7.0; n
= 49, p (paired t-test) = 0.66). The mean fatigue score
on recruitment was 61.6 (median 60, interquartile range
50-70; n = 49), and after one year was 59.6 (median and
interquartile range unchanged; n = 46).
Conformity to case definitions was assessed on fol-
low up. Numbers of subjects conforming to CDC
(1994) and Canadian definitions were reduced com-
pared with recruitment, though conformity to case
definitions was unchanged for 38 respondents (76%).
At recruitment, 49 subjects conformed to the CDC
(1994) definition, but only 44 on follow up. 31 subjects
conformed to the Canadian definition on recruitment;
four no longer conformed at follow-up, but three addi-
tional subjects did.
Discussion
Objective-Based Evaluation
The case ascertainment methods worked effectively, in
different communities, while the secondary care study
showed duplicate entries could be readily detected.
Regular follow-up is feasible, although a larger scale
study is needed to assess drop-out rates. A disease reg-
ister for ME/CFS can be established and managed in
compliance with legal and ethical requirements. Our
data transmission and processing methods are demon-
strably secure. Researchers have used the register to
identify participants for other studies, e.g. of gene
expression. Little data is missing, but case ascertain-
ment is not comprehensive; this was not achievable in
Table 3 Age and Sex Distribution among Disease Register Invitees, Participants, and Those Declining Invitation
All Invitees Not accepting Invitation Disease Register Participants
No.
cases
% total
(95% confidence interval)
No.
cases
% total
(95% confidence interval)
No.
cases
% total
(95% confidence interval)
Sex
Male 42 19.4 (7.2 - 31.7) 8 14.3 (0.0 - 39.0) 34 21.3 (7.2 - 35.3)
Female 174 80.6 (74.6 - 86.6) 48 85.7 (75.6 - 95.8) 126 78.8 (71.5 - 86.0)
Age group
< 25 26 12.3 (0.0 - 24.8) 6 10.7 (0.0 - 36.0) 20 12.5 (0.0 - 27.3)
25-44 73 33.8 (22.7 - 44.9) 23 41.1 (20.6 - 61.6) 50 31.3 (18.1 - 44.4)
45-64 132 61.1 (52.6 - 69.6) 32 57.1 (39.6 - 74.6) 100 62.5 (52.8 - 72.2)
65+ 6 2.8 (0.0 - 16.2) 1 1.8 (0.0 - 29.3) 5 3.1 (0.0 - 18.7)
Ethnicity
White British 157 72.6 (65.6 - 79.8) 12 21.4 (0.0 - 45.1) 145 90.6 (85.8 - 95.5)
Other 12 5.6 (0.0 - 18.8) 1 1.8 (0.0 - 28.3) 11 6.9 (0.0 - 22.1)
Not stated 47 21.8 (9.7 - 33.8) 43 76.8 (63.9 - 89.7) 4 2.5 (0.0 - 18.1)
Region
London 29 13.4 (0.8 - 26.1) 16 28.6 (6.0 - 51.2) 13 8.1 (0.0 - 23.3)
East Anglia 81 37.5 (26.7 - 48.3) 15 26.8 (3.9 - 49.7) 66 41.3 (29.1 - 53.4)
Yorks./
Humberside
105 48.6 (38.9 - 58.4) 25 44.6 (24.8 - 64.5) 80 50.0 (38.8 - 61.2)
Not stated 1 0.4 (0.0 - 14.9) - 0.0 1 0.6 (0.0 - 16.4)
TOTAL 216 100.0 56 100.0 160 100.0
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the particular circumstances of ME/CFS. We estab-
lished effective project management, including partici-
pation by people with ME/CFS and carers in the
Project Steering Group.
Interpretation of Statistical Findings
The results confirm that the Canadian definition [19]
defines a subset of cases conforming to CDC(1994) [18].
Use of both definitions enabled us to take advantage of
the sensitivity of the former and specificity of the latter.
We attempted to validate the epidemiological case
definition [20]. Use of this as an adjunct to the CDC
1994 definition does mitigate under-ascertainment, but
it is less inclusive than hoped. It includes some cases
excluded by the CDC 1994 definition, but excludes
many cases who do meet its requirements.
Disease register participants appear similar to descrip-
tive epidemiological study cases in proportions conform-
ing to various case definitions. Register participants are
rather older on average than descriptive epidemiological
study subjects, with a rather higher proportion of males.
More than three-quarters of disease register participants
Table 4 Severity distribution among disease register participants and non-participants
Participants
(n = 158)
Non-
Participants
(n = 58)
95% confidence interval
(difference in percentages)
No. % total No. % total
How often do you have tiredness/fatigue?
Occasionally 1 0.6 0 0.0 -0.6 - 1.9
< 3 times/week 6 3.8 2 3.4 -5.3 - 6.0
Every day or nearly every day 151 95.6 56 96.6 -6.8 - 4.8
Were your activities (personal, social, professional, at home) affected by the
symptoms of tiredness/fatigue?
Not at all 0 0.0 0 0.0 0.0 - 0.0
A little 1 0.6 0 0.0 -0.6 - 1.9
Needed to reduce 35 22.2 13 22.4 -13.1 - 12.5
Can no longer do 122 77.2 45 77.6 -13.2 - 12.5
Would you say that your activities were reduced to < 50% than before you
fell ill?
Yes, by > 50% 144 91.1 48 82.8 -2.5 - 19.3
No, by 50% or less or not at all 11 7.0 5 8.6 -10.1 - 6.8
Don’t know 3 1.9 5 8.6 -14.4 - 1.0
Would you say that your fatigue is debilitating and affects your mental and
physical functioning?
Yes 153 96.9 55 94.8 -4.4 - 8.5
No 3 1.9 1 1.7 -3.9 - 4.2
Don’t know 2 1.3 1 1.7 -4.3 - 3.4
Pain level (where 0 = no pain, and 10 = pain as bad as possible)
Mean 5.3 5.6
95% confidence interval Standard deviation 4.9 - 5.7 4.5 - 6.7
Median 2.5 2.1
6 6
Fatigue level on recruitment (where 0 = no problem, and 100 = the most
severe health impediment)
Mean 66.0 66.8
95% confidence interval 63.0 - 69.0 55.6 - 78.0
Standard deviation 18.3 38.0
Median 60 < 70 60 < 70
Table 5 Duration of illness prior to recruitment
Duration
(years)
Males Females All Participants
No.
cases
%
total
No.
cases
%
total
No.
cases
%
total
< 2 - 0.0 1 1.3 1 1.0
2 < 5 2 8.7 18 22.8 20 19.6
5 < 10 10 43.5 23 29.1 33 32.3
10 < 20 9 39.1 25 31.6 34 33.3
20+ 2 8.7 12 15.2 14 13.7
TOTAL 23 100.0 79 100.0 102 100.0
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were female. The modal age (nearly two-thirds of
respondents), was 45-64, whereas previous research has
suggested a modal age of 25-44 [22]. This may indicate
a cohort effect.
Conformity to case definitions varied through time,
suggesting that period prevalence rather than point pre-
valence may be appropriate in descriptive epidemiologi-
cal studies. Use of formal definitions to identify cases of
a syndrome is unsatisfactory, because boundaries are
arbitrary and overlap with other syndromes [23], and
different case definitions produce different findings in
ME/CFS [24,25]. Until phenotypes are defined in terms
of underlying pathology, this is unavoidable. However,
this does not impede the register’s purpose, to under-
take long-term follow-up, and create a sampling frame
for further studies.
What this study adds
This is the first systematic attempt to develop a popula-
tion-based disease register specific to ME/CFS. Partici-
pation was voluntary, and we depended on GPs for
recruitment of subjects. Many GPs remain reluctant to
diagnose ME/CFS [13]. Furthermore, reliance on norma-
tive case definitions to determine eligibility for inclusion
may result in under-ascertainment, as conformity varies
over time.
The study confirmed the feasibility of our methods of
case identification, data processing, transmission, storage
and analysis, and demonstrated the potential of GP elec-
tronic records for identifying patients suitable for regis-
tration. Our study met Newton and Garner’s
requirements [10] of robust and appropriate case defini-
tions, unbiased case ascertainment, and procedures for
identifying duplicates and for follow-up.
Future Developments
For the future, we propose to continue to recruit to the
register and to develop linked infrastructure facilities,
including a tissue sample bank, to which register partici-
pants will be invited to contribute blood samples, e.g. to
facilitate nested case-control studies of particular out-
comes, with access to stored biological material and
detailed follow-up data. A post mortem tissue archive is
also proposed, and disease register participants will be
invited to make advance declarations of willingness to
contribute tissues after death.
Other complementary initiatives include the National
Outcomes Database, an important infrastructure facil-
ity which collates patient data from NHS ME/CFS Col-
laborative clinical services[26]. This, though larger,
differs significantly from the disease register. It is
based on secondary care referrals, lacks a population
base, and uses the broader case definition advocated
by NICE [27].
Extending the use of the disease register as a sampling
frame will require capacity to flag records indicating
involvement in particular studies, to define additional
data fields, and to link records to records in other data-
bases. For outcomes assessment, a disease-specific
patient-reported outcome measure (PROM) is needed,
but meanwhile the London Handicap Scale [28], a six-
item validated instrument which facilitates inter-group
comparisons, may be useful [29].
Extending the register to national coverage will
require a major system upgrade, possibly involving a
multiple tier architecture, including an application ser-
ver to facilitate remote access for data collection and
interrogation, a backend database server, and an offline
data store to warehouse captured data. It also requires a
web services API (Application Programming Interface)
using XML, enabling authorised users to perform vali-
dated data submission as well as certain analyses of
aggregated data from remote locations, to minimise data
input errors and increase usability.
Conclusions
ME/CFS is a complex condition. This Disease Register
pilot study has validated the methods used to set it up
and has provided the basis for a range of initiatives to
develop the evidence base needed to understand causes,
clinical interventions and access to social support
needed to address this challenging disease.
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